On November 15, 2024, the Food and Drug Administration sanctioned revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia characterized by a ...
On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
On October 29, 2024, the Food and Drug Administration approved asciminib (Scemblix, Novartis AG) for adults who have just been diagnosed with Philadelphia chromosome-positive chronic myeloid leukemi...
Acute myeloid leukemia (AML)Acute Myeloid Leukemia (AML) is a critical and aggressive form of blood cancer that necessitates advanced treatment options for better patient outcomes. Recently, CAR T Cel...
Introduction CAR T cell therapy is the breakthrough treatment against various kinds of leukemias, particularly B-cell ALL. In this treatment, genetically modified T cells are specifically designed to...
Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become cancerous. This leads to the buildup of malignan...
Discover the science behind CAR T Cell therapy treatment in India! Explore how this revolutionary treatment transforms your immune cells into cancer fighters. Read our blog now to learn more about t...
Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's ...
Dec 2022: Olutasidenib (Rezlidhia) capsules were approved by the Food and Drug Administration (FDA) for adult patients with relapsed or resistant acute myeloid leukaemia (AML) who have a suscepti...
Dec 2022: A new Monday-Wednesday-Friday dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn has been approved by the Food and Drug Administration (Rylaze, Jazz Pharmaceuticals). P...